Expanding role of SGLT2 inhibitors: From cardioprotection in T2DM to HF management and renoprotection
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are playing an increasing role beyond glucose lowering and cardioprotection in patients with type 2 diabetes mellitus (T2DM). They are now recognized by international guidelines as one of the  first-line treatments for patients with heart failure with  reduced ejection fraction (HFrEF) based on significant  benefits demonstrated in HFrEF trials. Their renoprotective  effect in patients with T2DM and chronic kidne y disease (CKD) has led to guideline recommendations  for their use in these populations, while emerging data from  CKD trials may further expand their role in CKD management.  At a recent webinar, experts discussed these important  developments with a focus on the benefits of empagliflozin in these patient populations.

New Molecule

7 New

New Indication

4 New

New Dosage Strength

1 New

Markings
Shape
Form
Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in